ABVC BioPharma (ABVC) Set to Announce Earnings on Monday

ABVC BioPharma (NASDAQ:ABVC) is projected to announce its Q3 2026 resultson Monday, November 16th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $0.11 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 16, 2026 at 4:00 PM ET.

ABVC BioPharma (NASDAQ:ABVC) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.37.

ABVC BioPharma Stock Performance

Shares of ABVC opened at $0.97 on Monday. The business has a 50-day moving average of $1.01 and a 200 day moving average of $1.24. ABVC BioPharma has a fifty-two week low of $0.71 and a fifty-two week high of $3.06. The firm has a market cap of $25.86 million, a P/E ratio of -3.23 and a beta of 0.47.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ABVC BioPharma in a report on Friday, September 11th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock presently has an average rating of “Sell”.

About ABVC BioPharma

ABVC BioPharma, Inc (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and oncology-related conditions, as well as certain medical devices. The company advances product candidates through preclinical and clinical development and works with research, development and commercialization partners.

ABVC’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions, along with oncology programs targeting cancer treatment.